Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation

Transplantation

Volumn 65, Issue 2, 1998, Pages 180-187

  Eckhoff, Devin E ^a   McGuire, Brendan M ^a   Frenette, Luc R ^a   Contreras, Juan L ^a   Hudson, Sharon L ^a   Bynon, J Stevenson ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GLUCOSE; INSULIN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; STEROID; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DIABETES MELLITUS; FEMALE; GLUCOSE METABOLISM; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER DISEASE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL;

EID: 0032570304     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199801270-00006     Document Type: Article

References (48)

1. Williams JW, Vera SR, Peters TG, van Voorst S. Survival following hepatic transplantation in the cyclosporine era. Am Surg 1986; 52: 291.
2. Klopmaker IJ, Haagsma EB, Gouw AS, Verver R, Sloof MJ. Azathioprine and prednisone immunosuppression versus maintenance triple therapy including cyclosporine for orthotopic liver transplantation. Transplantation 1989; 48: 814.
3. Powell-Jackson P, Poison RJ, Williams R. Post-operative management in liver transplantation. In: Calne RY, ed. Liver transplantation, 2nd ed. Orlando, FL: Grune & Stratton, 1987: 253.
4. Starzl TE. Liver transplantation. In: Winter PM, Kang YG, eds. Hepatic transplantation. New York: Praeger Scientific, 1986: 3.
5. Starzl TE, Iwatsuki S, Shaw BW Jr, et al. Analysis of liver transplantation. Hepatology 1984; 4 (suppl): 47S.
6. Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. N Engl J Med 1989: 321: 1014, 1092.
7. Busuttil RW, McDiarmid S, Klintmalm GB, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331(17): 1110.
8. Neuhaus P, Bechstein WO, Blumhardt G, et al. Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994; 334: 423.
9. Neuhaus P, Blumhardt G, Bechstein WO, et al. Comparison of FK506 and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. Transplantation 1995; 59(1): 31.
10. Millis JM, Woodle ES, Piper JB, et al. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. Transplantation 1996; 61(9): 1365.
11. McDiarmid S. Mycophenolate mofetil in liver transplantation. Clin Transplant 1996; 10: 140.
12. Kino T, Hatanaka H, Hashimoto M; et al. FK506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physicochemical and biological characteristics. J Antibiot (Tokyo) 1987; 40: 1249.
13. Kino T, Hatanaka H, Miyata S, et al. FK506, a novel immunosuppressant isolated from a Streptomyces. I. Immunosuppressive effect of FK506 in vitro. J Antibiot (Tokyo) 1987; 40: 1256.
14. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62(7): 920.
15. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharmacol Res 1990; 7: 161.
16. Eugui EM, Allison AC. Immunosuppressive activity of mycophenolate mofetil. Ann NY Acad Sci 1993; 685: 309.
17. Matthews TR. Discovery and rationale for the development of mycophenolate mofetil. In: Leiberman R, Mukherjee A, eds. Principles of drug development in transplantation and autoimmunity. Austin, TX: RG Landes, 1994: 437.
18. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10: 77.
19. Baltzan M, Shoker A, Baltzan R. Mycophenolate mofetil study. Transplantation 1997; 63(1): 173.
20. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients. Transplantation 1997; 63(1): 39.
21. Danovitch G, Deierhoi M, Ferguson R, Linna J, Monroe S, Tomlanovich S. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996; 61(5): 722.
22. Keown P, Hayry P, Mathew T, et al. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61(7): 1029.
23. Freise CE, Herbert M, Osorio RW, et al. Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation. Transplant Proc 1993; 25: 1758.
24. Duvoux C, Pawlotsky JM, Cherqui D, et al. Serial quantitative determination of hepatitis C virus RNA levels after liver transplantation. Transplantation 1995; 60(5): 457.
25. Alessiani M, Spada M, Dionigi P, et al. Combined immunosuppressive therapy with tacrolimus and mycophenolate mofetil for small bowel transplantation in pigs. Transplantation 1996; 62(5): 563.
26. Zucker K, Rosen A, Tsaroucha A, et al. Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and Cellcept in combination therapy. Transplant Proc 1997; 29: 334.
27. Jindal RM, Popescu I. Renal dysfunction associated with liver transplantation. Postgrad Med J 1995; 71(839): 513.
28. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pre-transplant renal function on survival after liver transplantation. Transplantation 1995; 59: 361.
29. Porayko MK, Textor SC, Krom RA, et al. Nephrotoxic effects of primary immunosuppression with FK506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc 1994; 69: 105.
30. Monsour HP, Wood RP, Dyer CH, Galati JS, Ozaki CF, Clark JH. Renal insufficiency and hypertension as long-term complications in liver transplantation. Semin Liver Dis 1995; 15(2): 123.
31. Sandborn WJ, Hay JE, Porayko MK, et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994; 19: 925.
32. Chan CY, DasGupta K, Baker AL. Cyclosporin A: drug discontinuation for the management of long-term toxicity after liver transplantation. Hepatology 1996; 24(5): 1085.
33. Myers BD, Sibley R, Newton L, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590.
34. Mora NP, Gonwa TA, Goldstein RM, Husberg BS, Klintmalm GB. Risk of postoperative infection after liver transplantation: a univariate and stepwise logistic regression analysis of risk factors in 150 consecutive patients. Clin Transplant 1992; 46: 443.
35. Kusne S, Fung JJ, Alessiani M, et al. Infections during a randomized trial comparing cyclosporine to FK506 immunosuppression in liver transplantation. Transplant Proc 1992; 24: 429.
36. Van Son WJ, The TH. Cytomegalovirus infection after organ transplantation: an update with special emphasis on renal transplantation. Transpl Int 1989; 2: 147.
37. Jindal RM, Popescu I, Schwartz ME, Emre S, Boccagni P, Miller CM. Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. Transplantation 1994; 58(3): 370.
38. Rizza MA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action. J Clin Endocrinol Metab 1982; 54: 131.
39. Kahn CR, Goldfine ID, Neville DM, DeMeyts P. Alteration in insulin binding induced by changes in vivo in the levels of glucocorticoids and growth hormone. Endocrinology 1978; 103: 1054.
40. Hahn HJ, Laube F, Lucke S, et al. Toxic effects of cyclosporine on the endocrine pancreas of Wistar rats. Transplantation 1986; 41: 44.
41. Mor E, Sheiner PA, Schwartz ME, Sukru E, Guy S, Miller CM. Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. Transplantation 1994; 58(3): 380.
42. Araya V, Rakela J, Wright T. Hepatitis C after orthotopic liver transplantation. Gastroenterology 1997; 112(2): 575.
43. Rosen HR, O'Reilly PM, Shackleton CR, et al. Graft loss following liver transplantation in patients with chronic hepatitis C (1). Transplantation 1996; 62(12): 1773.
44. Gretch DR, Bacchi CE, Corey L, et al. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology 1995; 22(1): 1.
45. Sheiner PA, Schluger LK, Emre S, et al. Retransplantation for recurrent hepatitis C. Liver Transplant Surg 1997; 3(2): 130.
46. Johnson MW, Washburn WK, Freeman RB, et al. Hepatitis C viral infection in liver transplantation. Arch Surg 1996; 131: 284.
47. Freeman RB, Tran S, Lee YM, Rohrer RJ, Kaplan MM. Serum hepatitis C RNA titers after liver transplantation are not correlated with immunosuppression or hepatitis. Transplantation 1996; 61(4): 542.
48. Lake JR, Fitzsimmons W. Outcome of hepatitis C virus-infected primary liver transplant patients treated with tacrolimus. Presented at the 15th annual meeting of the American Society of Transplant Physicians, May 26-30, 1996, Chicago, IL.